Opendata, web and dolomites

NovAnI SIGNED

Indentification and optimisation of novel anti-infective agents using multiple hit-identification strategies

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NovAnI project word cloud

Explore the words cloud of the NovAnI project. It provides you a very rough idea of what is the project "NovAnI" about.

unconventional    context    mode    fact    given    coupling    first    place    aureus    staphylococcus    diseases    synergistic    vitamin    antibacterial    circumventing    infections    biosynthetic    organic    positive    threat    employing    combination    goals    pathogens    drugs    anti    repair    cell    biochemists    flexibility    chemistry    excellent    identification    mycobacterium    dnan    der    clamp    crossing    deaths    hit    mrsa    dxs    interdisciplinary    pharmacologists    gram    return    selectivity    million    negative    absent    serious    inhibitors    give    synthetic    methicillin    un    me    investment    protein    edge    transporters    resistance    exhaustion    platform    crystallographers    emergence    biochemical    few    antimalarial    erc    sliding    polymerase    urgently    action    health    difficult    antituberculotic    infectives    agents    energy    causative    builds    drug    position    explored    resistant    collaborations    agent    rapid    provides    humans    small    incidence    peculiar    bacteria    molecule    cutting    infective    wall    medicinal    expertise    scaffolds    importers    thereby    dna    potentially    strategies    tuberculosis   

Project "NovAnI" data sheet

The following table provides information about the project.

Coordinator
HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH 

Organization address
address: INHOFFENSTRASSE 7
city: BRAUNSCHWEIG
postcode: 38124
website: www.helmholtz-hzi.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 1˙499˙367 €
 EC max contribution 1˙499˙367 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2017-STG
 Funding Scheme ERC-STG
 Starting year 2018
 Duration (year-month-day) from 2018-02-01   to  2023-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH DE (BRAUNSCHWEIG) coordinator 1˙499˙367.00

Map

 Project objective

Given the rapid emergence of anti-infective resistance, drugs with a novel mode of action are urgently needed. Because of an exhaustion of existing strategies, a low return on investment and the fact that anti-infectives are difficult to develop (e.g., crossing the peculiar cell wall of Mycobacterium tuberculosis), promising un(der)explored targets and unconventional hit-identification strategies are needed.

I have selected three anti-infective targets based on their biochemical context for which few or no small-molecule inhibitors are known:

1) The antimalarial and antituberculotic drug target DXS is part of a unique biosynthetic pathway for pathogens that is absent in humans, thereby circumventing selectivity issues. Both diseases are a serious health threat with around 1.9 million deaths per year. 2) Energy-coupling factor transporters are essential vitamin importers for pathogens such as Staphylococcus aureus, the causative agent of methicillin-resistant Staphylococcus aureus (MRSA) infections. 3) The DNA polymerase sliding clamp DnaN has polymerase and DNA repair activities and is an excellent drug target for the development of antibacterial agents against Gram-negative and –positive bacteria given the low incidence of resistance development.

I will address these targets, employing a unique combination of potentially synergistic hit-identification strategies that take into account protein flexibility, provide access to novel scaffolds and give me a cutting edge for the development of novel anti-infectives.

This ERC proposal builds on my experience with the first two targets and provides an excellent platform for the new target DnaN. My expertise in synthetic organic and medicinal chemistry and established hit-identification strategies together with my collaborations with protein crystallographers, biochemists and pharmacologists place me in an excellent position for not only achieving the goals of this interdisciplinary proposal but also going beyond it.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NOVANI" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NOVANI" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

evolSingleCellGRN (2019)

Constraint, Adaptation, and Heterogeneity: Genomic and single-cell approaches to understanding the evolution of developmental gene regulatory networks

Read More  

IMMUNOTHROMBOSIS (2019)

Cross-talk between platelets and immunity - implications for host homeostasis and defense

Read More  

FunDiT (2019)

Functional Diversity of T cells

Read More